Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT06180278)
A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins and B-cell counts in participants with NMOSD who discontinue treatment. The objectives include: 1. To establish the nadir in circulating immunoglobulins (Ig) during chronic treatment with inebilizumab and ascertain the time needed to ensure restoration of pre-treatment baseline serum levels of IgG and IgM after discontinuation of treatment 2. To characterize B-cell counts throughout treatment with inebilizumab and after discontinuation until repletion of Immunoglobulin (Ig levels) 3. To assess long-term safety of inebilizumab 4. To assess other long-term effects of inebilizumab
Who can join: Review the eligibility criteria below.
Location: Wayne State University School of Medicine — Detroit, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Wayne State University School of Medicine — Detroit, Michigan
- Baylor College of Medicine — Houston, Texas
- Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK) - Ophtalmology — Hong Kong,
- Vseobecna fakultni nemocnice v Praze - Neurologicka klinika — Prague,
- Szegedi Tudományegyetem, à OK, Szent-Györgyi Albert Klinikai Központ - Neurológiai Osztály — Szeged, Csongrád megye
- Uniwersyteckie Centrum Kliniczne WUM - Oddzial Kliniczny Neurologii — Warsaw, Masovian Voivodeship
- M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM — Katowice, Silesian Voivodeship
- National Cancer Center - Neurology Clinic — Goyang-si, Gyeonggido [Kyonggi-do]
- Seoul National University Hospital — Seoul, Seoul Teugbyeolsi [Seoul-T'ukp
- Samsung Medical Center - Pediatric Neurology — Seoul, Seoul Teugbyeolsi [Seoul-T'ukp
- Khon Kaen University, Srinagarind Hospital - Division of Neurology, Depart — Khon Kaen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuromyelitis Optica Spectrum Disorder
- Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD — Washington D.C., District of Columbia
- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy — Aurora, Colorado
- Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — Washington D.C., District of Columbia
- A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) — Denver, Colorado
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder — La Jolla, California
Explore by condition: All Neuromyelitis Optica Spectrum Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.